Dr. Naveen Kumar Yarlagadda, MD

Dr. Yarlagadda practices at Central Arkansas Radiation Therapy Institute Inc in Little Rock, Arkansas.

Dr. Yarlagadda's NPI, 1396013363, was assigned on December 6, 2011. Dr. Yarlagadda holds Arkansas license E10364.

Dr. Yarlagadda's primary practice is Central Arkansas Radiation Therapy Institute Inc, at 8901 Carti Way, Little Rock, AR 72205 in Pulaski County. The practice phone is (501) 906-3000.

Dr. Yarlagadda's primary practice is Central Arkansas Radiation Therapy Institute Inc in Little Rock, Arkansas. Dr. Yarlagadda is also affiliated with Baptist Health Medical Center-Little Rock. The medical group on file is Arkansas Health Group. Dmand AI also links Dr. Yarlagadda to 3 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yarlagadda practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Yarlagadda's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Yarlagadda is licensed in Arkansas.

CMS data shows 95,112 Medicare services from Dr. Yarlagadda across 77 procedure codes in 2024, for 952 Medicare patients. Medicare paid $1,573,788 for them.

CMS counts 952 Medicare patients who saw Dr. Yarlagadda in 2024. The largest group is 65 to 74, with 377 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yarlagadda's median patient age at 69, with 60% women.

In 2024, Dr. Yarlagadda wrote 1,505 Medicare Part D claims for 259 patients. 78% of them were for generic drugs. CMS names the drug for 1,173 of them, across 42 drugs with 11 or more claims each, at $909,604 in total drug cost. In 2023, CMS named 558 claims across 22 drugs.

Dr. Yarlagadda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Yarlagadda, published from 2018 to 2022. 2021 was the busiest year, with 3. The most frequent topics are Multiple Myeloma, Bone Marrow and Gene Expression Profiling. Dr. Yarlagadda has published most often in Am J Hematol. Dr. Yarlagadda's most frequent co-authors are Meera Mohan, MD, Carolina D. Schinke, MD and Sharmilan Thanendrarajan, MD.

CMS Open Payments shows 38 general payments to Dr. Yarlagadda from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 85% of the total. AstraZeneca Pharmaceuticals LP paid the most, $17,237.